SILK ROAD MEDICAL INC (SILK) Fundamental Analysis & Valuation
NASDAQ:SILK • US82710M1009
Current stock price
27.49 USD
-0.01 (-0.04%)
At close:
27.49 USD
0 (0%)
After Hours:
This SILK fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. SILK Profitability Analysis
1.1 Basic Checks
- SILK had negative earnings in the past year.
- SILK had a negative operating cash flow in the past year.
- SILK had negative earnings in each of the past 5 years.
- SILK had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
- Looking at the Return On Assets, with a value of -20.96%, SILK is in line with its industry, outperforming 51.87% of the companies in the same industry.
- SILK has a Return On Equity (-36.55%) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -20.96% | ||
| ROE | -36.55% | ||
| ROIC | N/A |
ROA(3y)-24.4%
ROA(5y)-27.56%
ROE(3y)-44.44%
ROE(5y)-50.06%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- SILK's Gross Margin of 74.28% is amongst the best of the industry. SILK outperforms 85.03% of its industry peers.
- SILK's Gross Margin has been stable in the last couple of years.
- The Profit Margin and Operating Margin are not available for SILK so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 74.28% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.03%
GM growth 5Y0.93%
2. SILK Health Analysis
2.1 Basic Checks
- SILK does not have a ROIC to compare to the WACC, probably because it is not profitable.
- SILK has more shares outstanding than it did 1 year ago.
- The debt/assets ratio for SILK is higher compared to a year ago.
2.2 Solvency
- SILK has an Altman-Z score of 4.49. This indicates that SILK is financially healthy and has little risk of bankruptcy at the moment.
- With a decent Altman-Z score value of 4.49, SILK is doing good in the industry, outperforming 72.73% of the companies in the same industry.
- SILK has a Debt/Equity ratio of 0.49. This is a healthy value indicating a solid balance between debt and equity.
- With a Debt to Equity ratio value of 0.49, SILK is not doing good in the industry: 64.17% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.49 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 4.49 |
ROIC/WACCN/A
WACC8.47%
2.3 Liquidity
- SILK has a Current Ratio of 7.63. This indicates that SILK is financially healthy and has no problem in meeting its short term obligations.
- Looking at the Current ratio, with a value of 7.63, SILK belongs to the top of the industry, outperforming 85.56% of the companies in the same industry.
- SILK has a Quick Ratio of 6.69. This indicates that SILK is financially healthy and has no problem in meeting its short term obligations.
- With an excellent Quick ratio value of 6.69, SILK belongs to the best of the industry, outperforming 83.96% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 7.63 | ||
| Quick Ratio | 6.69 |
3. SILK Growth Analysis
3.1 Past
- The earnings per share for SILK have decreased by -2.13% in the last year.
- Looking at the last year, SILK shows a quite strong growth in Revenue. The Revenue has grown by 17.54% in the last year.
- The Revenue has been growing by 38.63% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-2.13%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-20%
Revenue 1Y (TTM)17.54%
Revenue growth 3Y33.05%
Revenue growth 5Y38.63%
Sales Q2Q%13.12%
3.2 Future
- The Earnings Per Share is expected to grow by 3.87% on average over the next years.
- The Revenue is expected to grow by 13.50% on average over the next years. This is quite good.
EPS Next Y-3.77%
EPS Next 2Y3.37%
EPS Next 3Y3.9%
EPS Next 5Y3.87%
Revenue Next Year16.35%
Revenue Next 2Y13.73%
Revenue Next 3Y12.46%
Revenue Next 5Y13.5%
3.3 Evolution
- The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. SILK Valuation Analysis
4.1 Price/Earnings Ratio
- The Price/Earnings Ratio is negative for SILK. In the last year negative earnings were reported.
- Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SILK. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y3.37%
EPS Next 3Y3.9%
5. SILK Dividend Analysis
5.1 Amount
- SILK does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
SILK Fundamentals: All Metrics, Ratios and Statistics
27.49
-0.01 (-0.04%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)08-07 2024-08-07/amc
Earnings (Next)11-06 2024-11-06/amc
Inst Owners3.3%
Inst Owner Change0%
Ins Owners28.49%
Ins Owner Change0%
Market Cap1.12B
Revenue(TTM)191.44M
Net Income(TTM)-56.54M
Analysts49.23
Price Target22.54 (-18.01%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)1.36%
Min EPS beat(2)-9.6%
Max EPS beat(2)12.31%
EPS beat(4)3
Avg EPS beat(4)8.54%
Min EPS beat(4)-9.6%
Max EPS beat(4)23.2%
EPS beat(8)6
Avg EPS beat(8)10.47%
EPS beat(12)7
Avg EPS beat(12)1.66%
EPS beat(16)9
Avg EPS beat(16)-1.22%
Revenue beat(2)2
Avg Revenue beat(2)3.84%
Min Revenue beat(2)1.28%
Max Revenue beat(2)6.4%
Revenue beat(4)3
Avg Revenue beat(4)3.97%
Min Revenue beat(4)-2.2%
Max Revenue beat(4)10.41%
Revenue beat(8)6
Avg Revenue beat(8)3.67%
Revenue beat(12)9
Avg Revenue beat(12)2.91%
Revenue beat(16)12
Avg Revenue beat(16)2.27%
PT rev (1m)-2.14%
PT rev (3m)6.94%
EPS NQ rev (1m)0%
EPS NQ rev (3m)3.92%
EPS NY rev (1m)-2.69%
EPS NY rev (3m)-2.45%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)1.22%
Revenue NY rev (1m)0.58%
Revenue NY rev (3m)1.15%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 5.83 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 7.22 | ||
| P/tB | 7.22 | ||
| EV/EBITDA | N/A |
EPS(TTM)-1.44
EYN/A
EPS(NY)-1.34
Fwd EYN/A
FCF(TTM)-0.89
FCFYN/A
OCF(TTM)-0.84
OCFYN/A
SpS4.71
BVpS3.81
TBVpS3.81
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -20.96% | ||
| ROE | -36.55% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 74.28% | ||
| FCFM | N/A |
ROA(3y)-24.4%
ROA(5y)-27.56%
ROE(3y)-44.44%
ROE(5y)-50.06%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.03%
GM growth 5Y0.93%
F-Score4
Asset Turnover0.71
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.49 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 81.1% | ||
| Cap/Sales | 1.11% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 7.63 | ||
| Quick Ratio | 6.69 | ||
| Altman-Z | 4.49 |
F-Score4
WACC8.47%
ROIC/WACCN/A
Cap/Depr(3y)251.08%
Cap/Depr(5y)187.13%
Cap/Sales(3y)3.05%
Cap/Sales(5y)2.22%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-2.13%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-20%
EPS Next Y-3.77%
EPS Next 2Y3.37%
EPS Next 3Y3.9%
EPS Next 5Y3.87%
Revenue 1Y (TTM)17.54%
Revenue growth 3Y33.05%
Revenue growth 5Y38.63%
Sales Q2Q%13.12%
Revenue Next Year16.35%
Revenue Next 2Y13.73%
Revenue Next 3Y12.46%
Revenue Next 5Y13.5%
EBIT growth 1Y-13.34%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year41.12%
EBIT Next 3Y19.7%
EBIT Next 5YN/A
FCF growth 1Y27.82%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y21.14%
OCF growth 3YN/A
OCF growth 5YN/A
SILK ROAD MEDICAL INC / SILK Fundamental Analysis FAQ
What is the fundamental rating for SILK stock?
ChartMill assigns a fundamental rating of 3 / 10 to SILK.
What is the valuation status of SILK ROAD MEDICAL INC (SILK) stock?
ChartMill assigns a valuation rating of 0 / 10 to SILK ROAD MEDICAL INC (SILK). This can be considered as Overvalued.
How profitable is SILK ROAD MEDICAL INC (SILK) stock?
SILK ROAD MEDICAL INC (SILK) has a profitability rating of 2 / 10.
How financially healthy is SILK ROAD MEDICAL INC?
The financial health rating of SILK ROAD MEDICAL INC (SILK) is 5 / 10.
What is the expected EPS growth for SILK ROAD MEDICAL INC (SILK) stock?
The Earnings per Share (EPS) of SILK ROAD MEDICAL INC (SILK) is expected to decline by -3.77% in the next year.